Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LFCR NASDAQ:MREO NASDAQ:NGNE NASDAQ:RPTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLFCRLifecore Biomedical$7.52-3.2%$7.56$4.33▼$8.85$281.32M0.64209,911 shs135,100 shsMREOMereo BioPharma Group$1.85+1.6%$1.81$1.47▼$4.72$294.15M0.471.67 million shs766,362 shsNGNENeurogene$19.00-5.4%$20.72$6.88▼$74.49$271.13M1.58220,311 shs123,015 shsRPTXRepare Therapeutics$1.76-2.8%$1.57$0.89▼$4.07$75.61M0.94289,606 shs90,416 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLFCRLifecore Biomedical+10.84%-2.14%+1.83%+15.45%+60.21%MREOMereo BioPharma Group+2.25%+5.20%+9.64%-34.06%-60.94%NGNENeurogene+7.96%+2.40%+4.47%+1.62%-48.96%RPTXRepare Therapeutics+2.84%+7.10%+16.03%+23.38%-35.59%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLFCRLifecore Biomedical$7.52-3.2%$7.56$4.33▼$8.85$281.32M0.64209,911 shs135,100 shsMREOMereo BioPharma Group$1.85+1.6%$1.81$1.47▼$4.72$294.15M0.471.67 million shs766,362 shsNGNENeurogene$19.00-5.4%$20.72$6.88▼$74.49$271.13M1.58220,311 shs123,015 shsRPTXRepare Therapeutics$1.76-2.8%$1.57$0.89▼$4.07$75.61M0.94289,606 shs90,416 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLFCRLifecore Biomedical+10.84%-2.14%+1.83%+15.45%+60.21%MREOMereo BioPharma Group+2.25%+5.20%+9.64%-34.06%-60.94%NGNENeurogene+7.96%+2.40%+4.47%+1.62%-48.96%RPTXRepare Therapeutics+2.84%+7.10%+16.03%+23.38%-35.59%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLFCRLifecore Biomedical 2.50Moderate Buy$8.007.24% UpsideMREOMereo BioPharma Group 3.20Buy$7.40296.78% UpsideNGNENeurogene 2.75Moderate Buy$46.17134.99% UpsideRPTXRepare Therapeutics 2.50Moderate Buy$4.50150.00% UpsideCurrent Analyst Ratings BreakdownLatest RPTX, NGNE, LFCR, and MREO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025LFCRLifecore BiomedicalKeyCorpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSector Weight8/25/2025MREOMereo BioPharma GroupJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$7.00 ➝ $8.007/10/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$7.00 ➝ $5.006/17/2025NGNENeurogeneCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$50.006/12/2025NGNENeurogeneBMO Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$22.00 ➝ $26.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLFCRLifecore Biomedical$128.87M2.17N/AN/A$0.04 per share186.50MREOMereo BioPharma Group$10M29.65N/AN/A$0.39 per share4.78NGNENeurogene$930K301.45N/AN/A$20.89 per share0.94RPTXRepare Therapeutics$53.48M1.45N/AN/A$3.56 per share0.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLFCRLifecore Biomedical-$38.72M-$1.31N/AN/AN/A-31.70%-846.51%-13.03%10/3/2025 (Estimated)MREOMereo BioPharma Group-$43.25M-$0.07N/AN/AN/AN/A-80.00%-66.94%11/11/2025 (Estimated)NGNENeurogene-$75.14M-$4.31N/AN/AN/AN/A-33.33%-30.34%11/17/2025 (Estimated)RPTXRepare Therapeutics-$84.69M-$2.58N/AN/AN/AN/A-78.25%-66.85%11/6/2025 (Estimated)Latest RPTX, NGNE, LFCR, and MREO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/3/2025Q1 2026LFCRLifecore Biomedical-$0.29N/AN/AN/A$26.68 millionN/A8/12/2025Q2 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$7.80 million$0.50 million8/11/2025Q2 2025NGNENeurogene-$1.15-$1.05+$0.10-$1.05N/AN/A8/8/2025Q2 2025RPTXRepare Therapeutics-$0.56-$0.39+$0.17-$0.39$2.50 million$0.25 million8/7/2025Q4 2025LFCRLifecore Biomedical-$0.09-$0.10-$0.01-$0.06$35.36 million$36.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLFCRLifecore BiomedicalN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/ANGNENeurogeneN/AN/AN/AN/AN/ARPTXRepare TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLFCRLifecore Biomedical113.762.841.77MREOMereo BioPharma GroupN/A8.138.13NGNENeurogeneN/A18.0718.07RPTXRepare TherapeuticsN/A6.306.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLFCRLifecore Biomedical83.36%MREOMereo BioPharma Group62.83%NGNENeurogene52.37%RPTXRepare Therapeutics85.09%Insider OwnershipCompanyInsider OwnershipLFCRLifecore Biomedical32.20%MREOMereo BioPharma Group5.50%NGNENeurogene11.64%RPTXRepare Therapeutics11.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLFCRLifecore Biomedical69037.41 million25.36 millionOptionableMREOMereo BioPharma Group40159.00 million150.26 millionOptionableNGNENeurogene9014.27 million12.61 millionOptionableRPTXRepare Therapeutics18042.96 million38.02 millionOptionableRPTX, NGNE, LFCR, and MREO HeadlinesRecent News About These CompaniesMPM Bioimpact LLC Has $808,000 Stock Holdings in Repare Therapeutics Inc. $RPTXSeptember 4, 2025 | marketbeat.comMPM Asset Management LLC Cuts Stock Position in Repare Therapeutics Inc. $RPTXSeptember 4, 2025 | marketbeat.comRepare Therapeutics Announces Licensing Deal and Strategic UpdatesAugust 12, 2025 | theglobeandmail.comRepare Therapeutics Inc. (RPTX) Reports Q2 Loss, Misses Revenue EstimatesAugust 8, 2025 | zacks.comRepare (RPTX) Q2 Loss Narrows 52%August 8, 2025 | fool.comRepare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial ResultsAugust 8, 2025 | financialpost.comFRepare Therapeutics Jumps 15% After $10M Licensing Deal With DebiopharmJuly 18, 2025 | uk.finance.yahoo.comRepare Therapeutics Inc. (RPTX) - Yahoo FinanceJuly 17, 2025 | finance.yahoo.comRepare inks licensing deal with Debiopharm for lunresertibJuly 16, 2025 | thepharmaletter.comTRepare finds suitor for paused PKMYT1 inhibitor in current partner DebiopharmJuly 16, 2025 | fiercebiotech.comFRepare Therapeutics Jumps After Hours On $267M Global Licensing Deal With Debiopharm; Retail Traders Rush InJuly 16, 2025 | msn.comRepare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for LunresertibJuly 15, 2025 | financialpost.comFRepare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for LunresertibJuly 15, 2025 | financialpost.comFRepare Therapeutics Enters Exclusive Worldwide Licensing Agreement with Debiopharm for LunresertibJuly 15, 2025 | businesswire.comRepare Therapeutics Inc (RPTX) - Investing.comJuly 3, 2025 | investing.comRepare Therapeutics Inc (RPTX) Stock Forums - Investing.comJune 30, 2025 | investing.comRepare Therapeutics Out-Licenses Discovery Platforms to DCx Biotherapeutics in Strategic DealJune 25, 2025 | insidermonkey.comRepare Therapeutics Updates Severance Benefits for ExecutivesJune 20, 2025 | tipranks.comRepare Therapeutics Strengthens Leadership with New Executive AppointmentJune 2, 2025 | tipranks.comRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | financialpost.comFRepare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial ResultsMay 13, 2025 | financialpost.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRPTX, NGNE, LFCR, and MREO Company DescriptionsLifecore Biomedical NASDAQ:LFCR$7.52 -0.25 (-3.22%) Closing price 04:00 PM EasternExtended Trading$7.52 0.00 (0.00%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.Mereo BioPharma Group NASDAQ:MREO$1.85 +0.03 (+1.65%) Closing price 04:00 PM EasternExtended Trading$1.85 0.00 (0.00%) As of 04:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Neurogene NASDAQ:NGNE$19.00 -1.08 (-5.38%) Closing price 04:00 PM EasternExtended Trading$19.20 +0.20 (+1.03%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.Repare Therapeutics NASDAQ:RPTX$1.76 -0.05 (-2.76%) Closing price 04:00 PM EasternExtended Trading$1.76 +0.00 (+0.28%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Why Micron Stock Could Outperform NVIDIA in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
